Who Paid My Doc
Mark Everley
Advanced Heart Failure and Transplant Cardiology Kansas City, MO Medical Doctor
NPI 1366612996 CMS profile 16353
4330 Wornall Rd Ste 2000, Kansas City, MO 64111
General payments
$119
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$6,965
Through program year 2025, Mark Everley of Kansas City, MO is reported in the CMS Open Payments database as having received $119 across 4 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,965 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 2nd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $103 | 2 | |
| 2024 | General | $15 | 2 |
Beside peers
- Mark Everley
- Advanced Heart Failure and Transplant Cardiology median
- Middle half of Advanced Heart Failure and Transplant Cardiology
- National median
In program year 2025, general payments to Mark Everley were reported at $103. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.
Show as a table
| Year | Mark Everley | Advanced Heart Failure and Transplant Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $863 | $224–$4,562 | $163 |
| 2020 | $0 | $452 | $122–$3,992 | $114 |
| 2021 | $0 | $550 | $159–$3,571 | $132 |
| 2022 | $0 | $729 | $221–$4,357 | $149 |
| 2023 | $0 | $1,002 | $309–$5,827 | $160 |
| 2024 | $15 | $931 | $273–$5,204 | $164 |
| 2025 | $103 | $1,024 | $289–$6,890 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 53 drugsPart D claims
3,241
Drug cost
$762,956
Branded share of claims
22.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 176 | $230,263 | |
| Entresto Sacubitril/Valsartan | Brand | 170 | $219,644 | |
| Jardiance Empagliflozin | Brand | 121 | $139,399 | |
| Xarelto Rivaroxaban | Brand | 27 | $29,849 | |
| Farxiga Dapagliflozin Propanediol | Brand | 32 | $24,070 | |
| Repatha Sureclick Evolocumab | Brand | 31 | $20,137 | |
| Sirolimus | Generic | 59 | $16,529 | |
| Ozempic Semaglutide | Brand | 15 | $14,249 | |
| Praluent Pen Alirocumab | Brand | 22 | $12,522 | |
| Tacrolimus | Generic | 73 | $9,955 |
The 10 drugs with the highest cost, of 53 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 46 billing codesPaid by Medicare
$76,810
Medicare patients
1,257
Services billed
1,954
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 58% | |
| Heart failure | 54% | |
| Arthritis | 50% | |
| Atrial fibrillation | 46% | |
| Chronic kidney disease | 46% | |
| Diabetes | 41% | |
| Depression | 28% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Advanced Heart Failure and Transplant Cardiology in Missouri
Andrew Sauer
Advanced Heart Failure and Transplant Cardiology · Lees Summit, MO
Gerard Oghlakian
Advanced Heart Failure and Transplant Cardiology · Springfield, MO
Brett Sperry
Advanced Heart Failure and Transplant Cardiology · Kansas City, MO
Shane Larue
Advanced Heart Failure and Transplant Cardiology · Hannibal, MO
Gregory Ewald
Advanced Heart Failure and Transplant Cardiology · Saint Louis, MO
Sumanth Prabhu
Advanced Heart Failure and Transplant Cardiology · Saint Louis, MO
Related records
Advanced Heart Failure and Transplant Cardiology in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Advanced Heart Failure and Transplant Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.